Page tree
Skip to end of metadata
Go to start of metadata

HPTN Study 069 (ACTG A5305) was a Phase II trial of maraviroc (Selzentry, Celsentri) to prevent HIV infection in men who have sex with men. The trial was conducted in 2012–2014 and made public in 2016.

See: Roy M. Gulick, Timothy J. Wilkin, Ying Q. Chen, Raphael J. Landovitz, K. Rivet Amico, Alicia M. Young, Paul Richardson, et al. “Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).” The Journal of Infectious Diseases 215, no. 2 (January 15, 2017): 238–46. doi:10.1093/infdis/jiw525.


Found 1 search result(s) for 069.

Page: 6.1 Sharon Hillier — Development and Application of Pre-exposure Prophylaxis (PrEP) (HIV/AIDS Research: Its History & Future Meeting)
... first studies of maraviroc alone, and in combination with tenofovir based regimens for PrEP by the HPTN 069 (2012–2016) team, and presented at CROI (Conference on Retroviruses and Opportunistic Infections) this year ...
Apr 27, 2021

  • No labels